Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era

Amelia H. Tran,Douglas E. Schaubel,David S. Goldberg,Vishnu S. Potluri,Peter L. Abt,Peter P. Reese

doi:10.1001/jama.2022.12868

Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era

Amelia H. Tran, Douglas E. Schaubel

Open Access

https://doi.org/10.1001/jama.2022.12868

Copy DOI

Journal: JAMA	Publication Date: Aug 22, 2022
Citations: 10

Affiliation: University of Pennsylvania, University of Miami, Hospital of the University of Pennsylvania

#Direct-Acting Antiviral Era #HCV-RNA Positive Donors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

This cohort study examines the validity of the Kidney Donor Profile Index’s hepatitis C virus (HCV) penalty during the direct-acting antiviral era by comparing 5-year allograft survival between recipients of kidneys from HCV-RNA–positive donors vs HCV-RNA–negative donors.

Full Text